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(1,000 U) injection intraperitoneally (i.p.). Each heart was 
rapidly excised and subjected to retrograde perfusion via  
the aorta, while immersed in a 160 mL water-jacketed 
reservoir, with a modified Krebs’ buffer (in mmol/L: 17.0 
dextrose, 120.0 NaCl, 25.0 NaHCO3, 2.5 CaCl2, 0.5 
EDTA, 5.9 KCl and 1.2 MgCl2). The perfusate was 
maintained at 37oC, kept at 80 mmHg constant pressure, 
aerated with 95% O2-5% CO2 and equilibrated at a pH of 
7.35-7.45. A side arm in the perfusion line was used for the 
infusion of 5 mL of autologous plasma with or without 
mitoQ (4, 40, 80 μM) or SS-31 (25, 50, 100 μM). A flow 
meter (T106, Transonic Systems, Inc., Ithaca, NY) 
monitored coronary flow.  Left ventricular end-systolic 
pressure (LVESP), left ventricular end-diastolic pressure 
(LVEDP), heart rate and the peak rates of rise and fall in 
the first derivative of left ventricular pressure (dP/dtmax and 
dP/dtmin, respectively) were monitored using a pressure 
transducer (SPR-524, Millar Instruments, Inc., Houston, 
TX) positioned in the left ventricular cavity and recorded 
using a Powerlab Station acquisition system (AD 
Instruments, Grand Junction, CO). Left ventricular 
developed pressure (LVDP) was calculated by subtracting 
LVEDP from LVESP. Cardiac function parameters were 
We hypothesized  that antioxidants specifically targeted to the mitochondria 
will attenuate myocardial I/R injury by limiting cardiac contractile 
dysfunction, cardiac tissue damage and SO release in isolated perfused rat 
hearts subjected to I/R compared to untreated I/R hearts. 
During myocardial ischemia, coronary blood flow interruption deprives 
cardiomyocytes of oxygen, glucose and fatty acids. Ischemic damage is 
exacerbated by a burst of reactive oxygen species (ROS) generated at 
reperfusion when oxygen interacts with damaged mitochondrial electron 
transport chains (ETC), especially uncoupled complexes I and III (Fig. 1,2). 
Nicotinamide adenine dinucleotide phosphate oxidase (Nox) activity can also 
release ROS, inducing additional tissue/organ damage1,2,3.   
Figure 3. Mitochondrial ROS stimulate ROS 
production outside mitochondria, increasing 
oxidative stress and apoptosis signaling cascade 
activation. ETC complexes and Nox4 are major 
ROS sources in dysfunctional mitochondria. 
Specific mitochondrial-targeted antioxidants 
exert cardioprotective effects.  Adapted from 
Bayeva  et al. 2013 and modified. 
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Isolated Rat Heart Preparation 
Male Sprague Dawley rats (275-325g, Charles River, Springfield, MA) were 
anesthetized with a pentobarbital sodium (60 mg/kg) and sodium heparin 
Figure 2.  
Myocardial I/R apparatus. 
measured every 5 min for 15 min to obtain stable baseline measurements. 
Ischemia was induced for 30 min by stopping Krebs’ buffer flow. After 
ischemia, Krebs’ buffer flow was restored while infusing 5 mL of plasma with 
or without mitoQ or SS-31 at a rate of 1 mL/min for 5 min. Cardiac function 
parameters were recorded every 5 min for 45 min. Three left ventricle sections 
from apex to middle were used in 1% 2,3,5- triphenyltetrazolium chloride 
(TTC) staining for 20 min at 37oC to detect infarct size. Frozen sections (8 
µm) of the left ventricle base were subjected to dihydroethidium (DHE) 
staining for 2 min at 22oC to fluoroscopically detect SO release. Fluorescence 
intensity is expressed in arbitrary units quantified by Image J.  
Statistical Analysis 
All data in the text and figures are presented as means ± SEM.  The cardiac 
function and TTC staining data were analyzed by ANOVA using post hoc 
analysis with the Student-Newman-Keuls test.  Probability values of <0.05 
were considered statistically significant. 
Figure 4. Time course of LVDP (upper left) and dP/dtmax (upper right) for I/R + mitoQ hearts and  
LVDP (lower left) and dP/dtmax (lower right) for I/R + SS-31 hearts. MitoQ and SS-31 restored post-
reperfused cardiac function significantly compared to untreated I/R hearts (*p<0.05, **p<0.01). 
Figure 6. Weight ratios of infarcted to at risk cardiac tissue in I/R as determined by TTC staining. 
Treatment with mitoQ (40, 80 μM) or SS-31 (25, 50, 100 μM) at reperfusion significantly reduced 
infarct size compared to untreated I/R hearts (**P<0.01). 
Figure 5. Representative cross sections of I/R left ventricles subjected to TTC staining. Viable tissue 
stained red while the infarcted tissue remained unstained (white). 
Figure 7. Representative photographs of left ventricular tissue from control (A), 4 μM mitoQ (B), 40 
μM mitoQ (C), 80 μM mitoQ (D) I/R hearts subjected to DHE staining at 40x magnification by 
fluorescence microscopy. I/R hearts treated with mitoQ (40, 80 μM) expressed less SO release than 
untreated I/R hearts, suggesting mitoQ attenuates SO release in myocardial I/R. 
The data suggest that inhibiting mitochondrial derived ROS with selective 
mitochondrial-targeted antioxidants, such as mitoQ and SS-31, can attenuate 
myocardial I/R injury by reducing ROS formation to limit cardiac contractile 
dysfunction and infarct size. Additionally, the data suggest that agents such 
as mitoQ and SS-31 can work expeditiously and effectively when 
administered at the time of coronary blood flow restoration. Therefore, 
treatment with mitoQ or SS-31 may be useful in the clinical setting in cases 
of myocardial infarction, where pretreatment is not always a practical option.  
Figure 2. Decreasing mitochondrial ROS production 
prevents destructive effects, including loss of 
membrane integrity. Modified from Szeto 2006.  
Surgical intervention or thrombolytic treatments can restore coronary blood 
flow. However, as blood flow reestablishes, oxidative stress leads to I/R injury. 
Clinical treatment remains a challenge as no pharmaceutical agents effectively 
limit I/R-induced damage. Mitochondria are implicated in I/R as a major 
source of ROS3,4,5. Excess ROS leads to mitochondrial and cardiac contractile 
dysfunction6. Conventional antioxidants have limited efficacy in myocardial 
I/R because they are not targeted selectively to where most I/R damage occurs, 
in mitochondria (Fig. 3)3,4,5. Mitoquinone (mitoQ, MW=600 g/mol), a 
coenzyme Q analog, easily crosses phospholipid bilayers and is driven by the 
large electrochemical membrane potential to concentrate mitoQ several 
hundred-fold within mitochondria. The respiratory chain reduces mitoQ to its 
active ubiquinol antioxidant form to limit myocardial I/R injury5. The SS-31 
(Szeto-Schiller) peptide ((D-Arg)-Dmt-Lys-Phe-Amide, MW=640 g/mol, 
Genemed Synthesis, Inc., San Antonio, TX)  is also of interest since it is cell-
permeable, specifically targeted to inner mitochondrial membranes based on 
its alternating cationic aromatic residue sequence, with an antioxidant 
dimethyltyrosine moeity. SS peptides scavenge ROS in I/R models4.  
Figure 1. Electrons leaking from complexes I 
and III are accepted by oxygen (O2) to generate 
superoxide (O2
-). Adapted from Szeto 2006.  
Although mitochondrial-targeted antioxidant pretreatment can effectively limit 
I/R injury, pretreatment is not always possible in cases of myocardial 
infarction. Therefore, evaluating cardioprotective efficacy of mitochondrial-
targeted antioxidants when given at reperfusion is of high significance. 
